Cboe Global Markets (CBOE)

The sleeper story here isn't the 18% revenue beat, it's that Cboe's highest-profile growth initiative just got quietly de-risked of any near-term revenue expectation: KPI contract fees are waived through the end of 2026 and management explicitly said volume projections are 'not really where our focus is', a sharp step down from last quarter's competitive-pricing talk. The obvious headline, a beat-and-raise with 73.3% EBITDA margins, is real but increasingly a function of expense cuts (opex down 3% year-over-year) rather than pure volume leverage, as the derivatives engine decelerated from 30% to 22% growth and the futures segment flipped from +2% to -5% on VIX weakness. The binding constraint isn't demand, it's regulatory and clearing readiness alongside management's own unwillingness to commit capital allocation specifics post-SPX deal: 'I cannot go into specifics as to your detailed questions there'. My view changes if the November KPI launch produces a quantified ADV or open-interest figure next quarter, or if the futures/VIX segment reaccelerates, either would confirm this is transitory rather than structural deceleration.